AME临床研究评论｜ADAURA试验：重新定义靶向治疗在可切除肺腺癌中的作用

文章预览

医学评论英文版原文： Zuluaga JA, Rojas L, Arrieta O, Cardona AF. ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma. AME Clin Trials Rev 2024;2:26. 被点评研究： Tsuboi M, Herbst RS, John T, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med 2023;389:137-47. ADAURA试验：重新定义靶向治疗在可切除肺腺癌中的作用 Jairo A. Zuluaga 1 , Leonardo Rojas 1 , Oscar Arrieta 2 , Andrés F. Cardona 1,3   1 Thoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia;  2 Thoracic Oncology Unit, Instituto Nacional de Cancerología – INCaN, México City, México;  3 Institute of Research and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia 翻译：陈建乐 引言 非小细胞肺癌（NSCLC）约占所有肺癌（LC）的85% [1] 。肺腺癌（LUAD）的发病率已显著下降，这主要 ………………………………